Prescription Drug Advertising: The FDA’s Continuing Efforts to Regulate and Clarify Drug Ads

Home) Item) Prescription Drug Advertising: The FDA’s Continuing Efforts to Regulate and Clarify Drug Ads

Transdermal is the only technical publication devoted exclusively to readers involved in development and production of pharmaceuticals delivered through the skin.

General Articles

In most cases, the FDA does not view advertisements before companies disseminate them; often it sees them at the same time as the consuming public. To ensure that the information in prescription-drug advertising is truthful, balanced, and accurately communicated to the public, the FDA’s Division of Drug Marketing, Advertising, and Communications (DDMAC) has been active in implementing new programs, such as the Bad Ad Program launched in 2010, to bolster its regulatory efforts. The FDA recently published a Year-in-Review report summarizing the first year of that program, which is aimed at healthcare professionals (HCPs) to assist in identifying bad ads.

This article reviews the results of the Bad Ad Program in its first year.

To read this entire article:

You may purchase this article now for personal use. Simply click the Buy Item button above, enter your payment details, and download the article. It will be available to you for 7 days for viewing, printing, or saving for future reference. All articles are copyrighted by CSC Publishing, Inc. and cannot be used for commercial purposes without express permission in writing from the Publisher. This includes but is not limited to: web posting, printing, or sharing via email.

Security:

Your payment information is forwarded in an encrypted form, using 40- or 128-bit Secure Socket Layer technology, only to our payment gateway (Authorize.net) for processing.

Acrobat:

To view an article, you must have Acrobat Reader installed on your computer. Click on the icon to download Acrobat Reader free of charge.